Consists of two main ingredients: SymSitive and licorice extract. SymSitive acts as a sensitivity regulator directly at the source of the hyper-reactivity. It calms the unpleasant sensation and increases the tolerance of hypersensitive skin. Licorice extract is a natural ingredient derived from glycyrrhiza inflata root extract. It is both an anti-inflammatory and an anti-oxidant, and so reduces redness and soothes irritation.

Applied after cleansing, it instantly hydrates, calms irritation and helps cover visible redness. This innovative formula combines two active ingredients: SymSitive and Licorice Extract. Alongside its two active ingredients, the cream also contains green pigments that cover and neutralise reddened skin resulting in an instant even-toned complexion. To minimise the chance of intolerance or skin reactions the formula is pure, while the packaging has been designed to protect it from contamination thanks to a dual valve system.

With 5% urea to restore skin’s natural balance and provide long lasting moisturisation. Use as often as required

Easily absorbed oil-in-water emulsion protects the skin and helps prevent further moisture loss. Can be used daily

For daily care of dry and very dry, tight facial skin. Can be used under makeup or after shaving. Fragrance free.

A gentle cleanser that will not wash away the skin’s natural protective barrier. It is enriched with moisturising Urea and Lactate to soothe dry to very dry skin.

Viticolor is a gel that has been designed to give a gradual, semi-permanent colour to depigmented skin in vitiligo. Viticolor contains a combination of 3 approved colouring agents, which give immediate but temporary colour to the skin with a pigmenting base containing DHA and erythrulose to give long-lasting colour. Viticolor Gel may be used during the treatment period and particularly during phototherapy

Molutrex contains a stable solution of potassium hydroxide (also known as KOH). This agent breaks down the hard keratin surface of the skin. When painted onto the molluscum blisters this sets off an irritant reaction which stimulates the body’s own immune system to attack the virus. The virus is destroyed and the blisters heal.

Ixekizumab is an IgG4 monoclonal antibody that binds with high affinity (<3 pM) and specificity to interleukin 17A (both IL-17A and IL-17A/F). Elevated concentrations of IL-17A have been implicated in the pathogenesis of psoriasis by promoting keratinocyte proliferation and activation, as well as in the pathogenesis of psoriatic arthritis by driving inflammation leading to erosive bone damage and pathological new bone formation. Neutralisation of IL-17A by ixekizumab inhibits these actions.

Baricitinib is a selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2. In isolated enzyme assays, baricitinib inhibited the activities of JAK1, JAK2, Tyrosine Kinase 2 and JAK3 with IC50 values of 5.9, 5.7, 53 and > 400 nM, respectively. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Within the intracellular signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which activate gene expression within the cell. Baricitinib modulates these signalling pathways by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing the phosphorylation and activation of STATs.